Improving Treatments - Improving Lives
AlphaVax, Inc. (AVX, Research Triangle Park, NC), a privately-held, clinical-stage biopharmaceutical company, has used its
proprietary alphavaccine vector platform technology to generate a portfolio of vaccine candidates for infectious disease
prevention and cancer immunotherapy. Three alphavccine candidates, targeting human cytomegalovirus, influenza A virus or
HIV-1, have been evaluated in four Phase
1 clinical trials. More recently, AVX has
focused efforts on the development of immunotherapeutic vaccines for the treatment of various cancers.
From these recent efforts, AVX has successfully progressed the development of its proprietary alphavaccine technology, to
create new, potentially first-in-class vaccines that engage the patient’s immune system to both recognize and fight off
various cancers. Results from AVX’s first trial evaluating its CEA alphavaccine in patients with Stage IV colon cancer,
showed the vector technology was able to “break self-tolerance” and a trend for enhanced survival in patients with CEA-specific
T cell responses. To follow up, AVX will initiate and complete clinical trials in
breast cancer, colon cancer (in Stage III patients) and melanoma over the next three years.